AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 342631 — intervention group
Group type: EXPERIMENTAL
Intervention: split-product vaccines, two-dose regimen
Number of subjects: 444
Study 342631 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent (A/New Jersey/76-A/Victoria/75) vaccines, high doses of split-product
Number of subjects: 444
Study 342631 — intervention group
Group type: COMPARATOR
Intervention: whole-virus vaccines
Number of subjects: 444
Study 31765053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists rated their own communication skills for anxious patients
Number of subjects: 70
Study 31765053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists rated their own communication skills for unmotivated patients
Number of subjects: 70
Study 31765053 — intervention group
Group type: COMPARATOR
Intervention: Students' overall empathy scores
Number of subjects: 70
Study 30358156 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (17.1 mmol)
Number of subjects: 0
Study 30358156 — intervention group
Group type: COMPARATOR
Intervention: Glycine (control amino acid)
Number of subjects: 0
Study 30358156 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 27653939 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 3 days
Number of subjects: 199
Study 27653939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 27653939 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin and Placebo
Number of subjects: 199
Study 25668167 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based screening (experimental arm)
Number of subjects: 176464
Study 25668167 — intervention group
Group type: COMPARATOR
Intervention: Cytology-based screening (control arm)
Number of subjects: 176464
Study 23240499 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine subunit strain A/California/7/2009/(H1N1)v
Number of subjects: 70
Study 20461336 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group (isometric, dynamic and stretching exercises)
Number of subjects: 180
Study 20461336 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance group (dynamic muscle and stretching exercises)
Number of subjects: 180
Study 20461336 — intervention group
Group type: COMPARATOR
Intervention: Control group (stretching exercises)
Number of subjects: 180
Study 18418962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine plus Western routine therapy
Number of subjects: 82
Study 18418962 — intervention group
Group type: COMPARATOR
Intervention: Western routine therapy (Control)
Number of subjects: 82
Study 15923120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lead placement on the posterior left ventricle
Number of subjects: 25
Study 15923120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lead placement on the anterior left ventricle
Number of subjects: 25
Study 15923120 — intervention group
Group type: COMPARATOR
Intervention: Active lead placement on the right ventricle (control)
Number of subjects: 25
Study 12844131 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral dexamethasone regimen (20 mg on day 1, 8 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Number of subjects: 20
Study 12844131 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dexamethasone regimen (12 mg on day 1, 4 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Number of subjects: 20
Study 12844131 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone regimen (125 mg IV on day 1, 40 mg orally on days 2 to 3) with aprepitant (125 mg on day 1, 80 mg on days 2 to 3)
Number of subjects: 20
Study 10325897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 500 micrograms twice daily
Number of subjects: 59
Study 10325897 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 800 micrograms twice daily
Number of subjects: 59
Study 8612314 — intervention group
Group type: COMPARATOR
Intervention: Ftorafur (FT) 600 mg/day
Number of subjects: 1254
Study 8612314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day
Number of subjects: 1254
Study 1787937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone 1%
Number of subjects: 58
Study 1787937 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (control group)
Number of subjects: 58
Study 7025416 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 7025416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 7025416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31429150 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma uric acid (PUA) concentrations
Number of subjects: 88
Study 31429150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional excretion of UA
Number of subjects: 88
Study 30501835 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based remote training and counselling
Number of subjects: 120
Study 30501835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 26654213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 118
Study 26654213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 25040829 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia in labour (31.5%, n = 66,317)
Number of subjects: 210708
Study 25040829 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia in labour
Number of subjects: 210708
Study 23193066 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles
Number of subjects: 10
Study 23193066 — intervention group
Group type: COMPARATOR
Intervention: Regular insoles
Number of subjects: 10
Study 23193066 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot condition
Number of subjects: 10
Study 23193066 — intervention group
Group type: COMPARATOR
Intervention: Regular footwear condition
Number of subjects: 10
Study 20798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic blood pressure (SBP)
Number of subjects: 0
Study 20798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in systolic blood pressure (SD.SBP)
Number of subjects: 0
Study 20798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in diastolic blood pressure (DBP variability)
Number of subjects: 0
Study 20798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean diastolic blood pressure (DBP)
Number of subjects: 0
Study 20798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in diastolic blood pressure (SD.DBP)
Number of subjects: 0
Study 18586814 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular electrical stimulation (FES)
Number of subjects: 5
Study 18586814 — intervention group
Group type: COMPARATOR
Intervention: Passive leg movement (control)
Number of subjects: 5
Study 16320349 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet adhesion and aggregation on the extracellular matrix measured with a cone‐and‐plate(let) analyzer (CPA)
Number of subjects: 88
Study 12366503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration <1 litre
Number of subjects: 17
Study 12366503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration ≥1 litre
Number of subjects: 17
Study 12366503 — intervention group
Group type: COMPARATOR
Intervention: No fluid administration (Control)
Number of subjects: 17
Study 11041318 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg per os)
Number of subjects: 0
Study 11041318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8773263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 122
Study 8773263 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 122
Study 8773263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 2055827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (10 g.kg body mass‐1.day‐1)
Number of subjects: 22
Study 2055827 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (5 g.kg body mass‐1.day‐1)
Number of subjects: 22
Study 7081096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day zinc supplementation
Number of subjects: 32
Study 7081096 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/day zinc supplementation
Number of subjects: 32
Study 7081096 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day zinc supplementation
Number of subjects: 32
Study 7081096 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/day zinc supplementation (placebo)
Number of subjects: 32
Study 31405875 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation and educational outreach visits
Number of subjects: 209
Study 31405875 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation and shared learning
Number of subjects: 209
Study 31405875 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation and both shared learning and educational outreach visits
Number of subjects: 209
Study 31405875 — intervention group
Group type: COMPARATOR
Intervention: Practice facilitation only
Number of subjects: 209
Study 28631901 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated ultra‐lightweight polypropylene implant (surface density 19 g/m2)
Number of subjects: 93
Study 28631901 — intervention group
Group type: COMPARATOR
Intervention: Lightweight polypropylene implant (surface density 42.7 g/m2)
Number of subjects: 93
Study 26700109 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D2 (ergocalciferol)
Number of subjects: 340
Study 26700109 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3 (cholecalciferol)
Number of subjects: 340
Study 26700109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 24938529 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 21917257 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation (Nav 1)
Number of subjects: 20
Study 21917257 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation (Nav 2)
Number of subjects: 20
Study 21917257 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (Fluoro)
Number of subjects: 20
Study 21205556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc in tablet form
Number of subjects: 200
Study 21205556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc in suspension form
Number of subjects: 200
Study 21205556 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended treatment for diarrhoea
Number of subjects: 200
Study 17395055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) therapy; delivered continuously for 30 minutes in patients and 2 hours in dogs
Number of subjects: 15
Study 16128874 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to drink 1.5 l of water per day
Number of subjects: 18
Study 16128874 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 18
Study 11870165 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² IV every 21 days
Number of subjects: 97
Study 11870165 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m², Doxorubicin 50 mg/m², and Cisplatin 50 mg/m² (CAP) IV every 21 days
Number of subjects: 97
Study 10197659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump prime only aprotinin (280 mg)
Number of subjects: 22
Study 10197659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8306012 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0
Study 8306012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 8306012 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 8306012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 20 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 40 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 60 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 60-80 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin greater than 100 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 80 mg daily
Number of subjects: 8
Study 3476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 100 mg daily
Number of subjects: 8
Study 29764571 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG localization and postoperative X‐ray localization
Number of subjects: 160
Study 29764571 — intervention group
Group type: COMPARATOR
Intervention: Body surface measurement and postoperative X‐ray localization
Number of subjects: 160
Study 29764571 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG localization during PICC placement
Number of subjects: 160
Study 29764571 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG localization
Number of subjects: 160
Study 27670795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spin‐echo proton density‐weighted magnetic resonance imaging
Number of subjects: 79
Study 27670795 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline superficial femoral artery volumes
Number of subjects: 79
Study 27670795 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year change in FV total volume
Number of subjects: 79
Study 24697960 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light with sodium perborate and distilled water
Number of subjects: 30
Study 24697960 — intervention group
Group type: COMPARATOR
Intervention: Diode laser with sodium perborate and distilled water
Number of subjects: 30
Study 22913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat patch containing iron chip
Number of subjects: 147
Study 22913409 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 147
Study 20713439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory transcutaneous electrical nerve stimulation (TENS) with therapeutic exercise
Number of subjects: 36
Study 20713439 — intervention group
Group type: COMPARATOR
Intervention: Placebo electrical stimulation with therapeutic exercise
Number of subjects: 36
Study 20713439 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 36
Study 18589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified harvesting technique of the semitendinosus (group A)
Number of subjects: 35
Study 18589267 — intervention group
Group type: COMPARATOR
Intervention: Standard harvesting technique (group B)
Number of subjects: 35
Study 15859526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed short-wave diathermy (PSWD) with mean power of 18 W (thermal effect)
Number of subjects: 103
Study 15859526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed short-wave diathermy (PSWD) with mean power of 1.8 W (athermal effect)
Number of subjects: 103
Study 15859526 — intervention group
Group type: COMPARATOR
Intervention: Sham short-wave diathermy treatment (control)
Number of subjects: 103
Study 11801587 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg/day
Number of subjects: 414
Study 11801587 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 5 mg/kg/day
Number of subjects: 414
Study 11801587 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B lipid complex (ABLC) 5 mg/kg/day
Number of subjects: 414
Study 11801587 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 414
Study 10401542 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight week rehabilitation programme combining group and individual therapies
Number of subjects: 67
Study 10401542 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 8904255 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 mu g in 10 ml normal saline)
Number of subjects: 40
Study 8904255 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml normal saline)
Number of subjects: 40
Study 8904255 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 mu g in 50 ml bupivacaine 0.125% at a rate of 6-10 ml/h)
Number of subjects: 40
Study 1919423 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment (NPT) programme
Number of subjects: 400
Study 1919423 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 400
Study 7114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamycin
Number of subjects: 64
Study 7114615 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitine alone
Number of subjects: 64
Study 31471246 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 40 mg
Number of subjects: 580
Study 31471246 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 80 mg
Number of subjects: 580
Study 31471246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 30276562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neuroticism
Number of subjects: 92
Study 30276562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher conscientiousness and extraversion
Number of subjects: 92
Study 30276562 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 92
Study 30115212 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of children and adolescents with suicidal ideation or behaviour
Number of subjects: 198
Study 30115212 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to prescribe antidepressants
Number of subjects: 198
Study 30115212 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty in managing this patient group
Number of subjects: 198
Study 30115212 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to services
Number of subjects: 198
Study 26273146 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel facilitated endotracheal tube intubation (Group TI)
Number of subjects: 66
Study 26273146 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube intubation (Group TT)
Number of subjects: 66
Study 24589724 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD273 urinary proteome-based classifier
Number of subjects: 165
Study 22525775 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 117
Study 22525775 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 117
Study 22525775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (AT/RT)
Number of subjects: 117
Study 19788364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen therapy (creams, tablets, rings)
Number of subjects: 0
Study 19788364 — intervention group
Group type: COMPARATOR
Intervention: Systemic estrogen therapy
Number of subjects: 0
Study 17971946 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN injection plus inhaled glucocortisteriods
Number of subjects: 37
Study 17971946 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocortisteriods only
Number of subjects: 37
Study 17971946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 15455619 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-TB test in pulmonary TB smear positive patients
Number of subjects: 129
Study 15455619 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-TB test in pulmonary TB smear negative patients
Number of subjects: 129
Study 15455619 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-TB test in patients with TB pleural effusion
Number of subjects: 129
Study 15455619 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-TB test in patients with TB lymphadenitis
Number of subjects: 129
Study 15455619 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-TB patients and healthy subjects)
Number of subjects: 129
Study 11447080 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 160
Study 11447080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 9586317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoleum
Number of subjects: 34
Study 9586317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 10548622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 1.5% lignocaine (group A)
Number of subjects: 135
Study 10548622 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group B)
Number of subjects: 135
Study 10548622 — intervention group
Group type: COMPARATOR
Intervention: No local injection (group C)
Number of subjects: 135
Study 2269086 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis programme for small groups including tooth cleaning, professional plaque removal, and local fluoridation.
Number of subjects: 190
Study 2269086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 190
Study 424490 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological assessment before management regimes
Number of subjects: 83
Study 424490 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological assessment
Number of subjects: 83
Study 424490 — intervention group
Group type: COMPARATOR
Intervention: Physiological tests of lung functioning, exercise tolerance test, reported symptoms, time off work, drop-out, and death
Number of subjects: 83
Study 31607677 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day plus rifaximin 1200 mg/day
Number of subjects: 44
Study 31607677 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day plus rifaximin 1200 mg/day
Number of subjects: 44
Study 31607677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29987559 — intervention group
Group type: EXPERIMENTAL
Intervention: REThink intervention (N=54)
Number of subjects: 165